Усиление эффективности кандидатной вакцины против гриппа сочетанием консервативных последовательностей гемагглютинина и М2 белка
https://doi.org/10.31631/2073-3046-2017-16-3-65-70
Аннотация
Ключевые слова
Об авторах
Л. М. ЦыбаловаРоссия
Л. А. Степанова
Россия
Р. Ю. Котляров
Россия
Е. А. Блохина
Россия
М. А. Шуклина
Россия
Е. С. Марданова
Россия
А. В. Коротков
Россия
М. В. Потапчук
Россия
Н. В. Равин
Россия
Список литературы
1. Sette A., Rappuoli R. Reverse vaccinology: Devecoping vaccines in the Era of Genomicsa. Immunity. 2010; 33 (4): 530 - 541.
2. Ebrahimi S., Tebianian M. Influenza A viruses: why focusing on M2e-based universal vaccines. Virus Genes. 2011; 42: 1 - 8.
3. Fiers W., De Filette M., El Bakkouri K., Schepens B. et al. M2e-based universal influenza A vaccine. Vaccine. 2009; 27: 6280 - 6283.
4. Stepanova L., Kotlyarov R., Kovaleva A., Potapchuk M., Sergeeva M., Tsybalova L. Protection against multiple influenza A virus strains induced by candidate recombinant vaccine based on heterologous M2e peptides linked to flagellin. PLoS ONE. 2015; 10 (3): 22.
5. Wang L., Hess A., Chang T., Wang Y. Wang Y.C., Champion J.A., Compans R.W. et al. Nanoclusters self-assembled from conformation-stabilized influenza m2e as broadly cross-protective influenza vaccines. Nanomedicine. 2013; 10: 473 - 482.
6. Schotsaert M., De Filette M., Fiers W., Saelens X. Universal m2 ectodomain-based influenza a vaccines: Preclinical and clinical developments. Expert Rev. Vaccine. 2009; 8: 499 - 508.
7. Turley C., Rupp R., Johnson C., Taylor D., Wolfson J. et al. Safety and immunogenicity of a recombinant m2e-flagellin influenza vaccine (stf2.4xm2e) in healthy adults. Vaccine. 2011; 29: 5145-5152.
8. Wang, T., Tan, G., Hai R., Pica N., Ngai L., Ekiert D.C.et al. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc. Natl. Acad. Sci. USA. 2010; 107: 18979 - 18984.
9. Corti D., Suguitan A., Pinna D., Silacci C., Fernandez-Rodriguez B.M., Vanzetta F. et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J. Clin. Invest. 2010; 120: 1663 - 1673.
10. Zang H., Wang L., Compans R., Wang B. Universal Influenza Vaccines, a Dream to Be Realized Soon. Viruses. 2014; 6 (5): 1974 - 1991.
11. Steel J., Lowen A., Wang T., Yondola M. Gao Q,, Haye K, et al. Influenza virus vaccine based on the conserved haemagglutinin stalk domain. MBio. 2010; 1: 1 - 9.
12. Zhou L., Ren R., Yang L., Bao C., Wu J., Wang D. et al. Sudden increase in human infection with avian influenza A(H7N9) virus in China, Semptember-December 2016 Western Pac Surveill Response J. 2017; 8 (1): 1 - 9.
13. Ekiert D., Friesen R., Bhabha G., Kwaks T., Jongeneelen M., Yu W. et al. A highly conserved neutralizing epitope on group 2 influenza a viruses. Science. 2011; 333: 843 - 850.
14. Gocnik M., Fislova T., Mucha V., Sladkova T. et al. J. of General virology. 2008; 89: 958 - 967.
15. Tsybalova L., Stepanova L., Kuprianov V., Blokhina E., Potapchuk M., Korotkov A. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e. Vaccine. 2015; 05: 3398 - 3406.
16. Bates J., Aaron H., James P., Jason M. Enhanced antigen processing of flagellin fusion proteins promotes the antigen-specific CD8+ T cell response independently of TLR5 and MyD88. J. Immunol. 2011; 186 (11):6255 - 62.
17. Jegerlehner N., Schmitz T., Storni M., Bachmann J. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J. Immunol. 2004; 172: 5598 - 5605.
Рецензия
Для цитирования:
Цыбалова Л.М., Степанова Л.А., Котляров Р.Ю., Блохина Е.А., Шуклина М.А., Марданова Е.С., Коротков А.В., Потапчук М.В., Равин Н.В. Усиление эффективности кандидатной вакцины против гриппа сочетанием консервативных последовательностей гемагглютинина и М2 белка. Эпидемиология и Вакцинопрофилактика. 2017;16(3):65-70. https://doi.org/10.31631/2073-3046-2017-16-3-65-70
For citation:
Tsybalova L.M., Stepanova L.A., Kotlyarov R.Yu., Blokhina E.A., Shuklina M.A., Mardanova E.S., Korotkov A.V., Potapchuk M.V., Ravin N.V. Strengthening the Effectiveness of the Candidate Influenza Vaccine by Combining Conserved Sequences of Hemagglutinin and M2 protein. Epidemiology and Vaccinal Prevention. 2017;16(3):65-70. (In Russ.) https://doi.org/10.31631/2073-3046-2017-16-3-65-70